Breaking News Instant updates and real-time market news.

2023-01-27 16:57:37 CINF Cincinnati Financial $105.48 / -0.235 (-0.22%) 16:57 01/27/23 01/27 16:57 01/27/23 16:57	Cincinnati Financial announces preliminary Q4 pretax catastrophe losses of $141M Cincinnati Financial announced that its consolidated fourth-quarter results are expected to include pretax catastrophe losses of approximately $141M, representing an impact on the fourth-quarter combined ratio of approximately 7.8 percentage points, based on estimated property casualty earned premiums. The company's five-year historical average contribution of catastrophe losses to the combined ratio is 3.9 percentage points for the fourth quarter. The catastrophe loss estimate includes $161M from Winter Storm Elliott, net of reinsurance and excluding any effects of reinstatement premiums assumed or ceded, in addition to less severe storms and favorable loss reserve development on previous catastrophe events, primarily ones that occurred in 2022. The estimate for total Q4 catastrophe losses incurred includes approximately $100M for the commercial lines insurance segment; $38M for the personal lines insurance segment; $2M for the excess and surplus lines insurance segment and $1M in total for Cincinnati Re and Cincinnati Global Underwriting Ltd. Estimated losses and expenses from catastrophe-related claims are expected to bring the company's fourth-quarter property casualty combined ratio to approximately 95%. The combined ratio before catastrophe losses for the quarter was approximately 2.5 percentage points better than that ratio for the first nine months of 2022 but continued to reflect increased uncertainty of estimated ultimate losses, due in part to elevated paid losses reflecting economic or other forms of inflation. Net written premium growth is estimated to be approximately 10% for the quarter.	07 Feb

2023-01-27 16:57:37

CINF

Cincinnati Financial

$105.48 / -0.235 (-0.22%)

16:57

01/27/23

01/27

16:57

01/27/23

16:57

Cincinnati Financial announces preliminary Q4 pretax catastrophe losses of $141M

Cincinnati Financial announced that its consolidated fourth-quarter results are expected to include pretax catastrophe losses of approximately $141M, representing an impact on the fourth-quarter combined ratio of approximately 7.8 percentage points, based on estimated property casualty earned premiums. The company's five-year historical average contribution of catastrophe losses to the combined ratio is 3.9 percentage points for the fourth quarter. The catastrophe loss estimate includes $161M from Winter Storm Elliott, net of reinsurance and excluding any effects of reinstatement premiums assumed or ceded, in addition to less severe storms and favorable loss reserve development on previous catastrophe events, primarily ones that occurred in 2022. The estimate for total Q4 catastrophe losses incurred includes approximately $100M for the commercial lines insurance segment; $38M for the personal lines insurance segment; $2M for the excess and surplus lines insurance segment and $1M in total for Cincinnati Re and Cincinnati Global Underwriting Ltd. Estimated losses and expenses from catastrophe-related claims are expected to bring the company's fourth-quarter property casualty combined ratio to approximately 95%. The combined ratio before catastrophe losses for the quarter was approximately 2.5 percentage points better than that ratio for the first nine months of 2022 but continued to reflect increased uncertainty of estimated ultimate losses, due in part to elevated paid losses reflecting economic or other forms of inflation. Net written premium growth is estimated to be approximately 10% for the quarter.

07
Feb

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks	Puma presents biomarker findings from Phase II study in HR+, TN breast cancer » 09:08 06/04/23 06/04 09:08 06/04/23 09:08 PBYI Puma Biotechnology $3.56 / +0.115 (+3.34%) Puma Biotechnology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 7th, 09:08 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events PBYI Puma Biotechnology $3.56 / +0.115 (+3.34%) 02/01/23 Puma's Nerlynx included in NCCN guidelines for HER2-positive breast cancer 12/07/22 Puma Biotechnology presents updated findings from TBCRC-022 trial PBYI Puma Biotechnology $3.56 / +0.115 (+3.34%) 08/05/22 H.C. Wainwright Puma Biotechnology price target lowered to $8 from $12 at H.C. Wainwright PBYI Puma Biotechnology $3.56 / +0.115 (+3.34%) 05/04/23 Puma Biotechnology reports Q1 adjusted EPS 9c, consensus (7c) 03/02/23 Puma Biotechnology reports Q4 EPS (7c), consensus 0c 06/13/23 Puma Biotechnology, Inc.
Hot Stocks	Amgen presents new LUMAKRAS CodeBreaK 200 CNS data at ASCO » 08:48 06/04/23 06/04 08:48 06/04/23 08:48 AMGN Amgen $218.03 / +3.76 (+1.75%) Amgen announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 7th, 08:48 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AMGN Amgen $218.03 / +3.76 (+1.75%) 05/18/23 Sanofi 'pleased' with Supreme Court's ruling on Amgen's asserted patent claims 05/18/23 Regeneron 'applauds' Supreme Court's striking down Amgen's patent claims 05/18/23 Supreme Court upholds Sanofi PCSK9 drug patent victory over Amgen 05/18/23 Supreme Court upholds Sanofi patent victory over Amgen AMGN Amgen $218.03 / +3.76 (+1.75%) 06/01/23 Wells Fargo Wells says Coherus' Humira biosimilar pricing 'actually good news' for AbbVie 05/16/23 Stifel Seagen likely to stay 'distanced' from deal price after FTC action, says Stifel 05/16/23 Jefferies Jefferies thinks Amgen-Horizon deal still gets done after 'speed bump' 05/03/23 Mizuho Amgen price target raised to $214 from $208 at Mizuho AMGN Amgen $218.03 / +3.76 (+1.75%) 04/27/23 Amgen raises FY23 adjusted EPS view to $17.60-$18.70 from $17.40-$18.60 04/27/23 Amgen reports Q1 adjusted EPS $3.98, consensus $3.85 04/27/23 Notable companies reporting after market close 03/01/23 Horizon Therapeutics reports Q4 EPS $1.21, consensus $1.09 AMGN Amgen $218.03 / +3.76 (+1.75%) 05/23/23 Amgen, J&J settle patent lawsuit over Stelara biosimilar, Reuters reports 05/17/23 Regeneron CEO backs regulators attempt to block Amgen deal, FT reports 05/16/23 FTC will sue to block Horizon Therapeutics takeover by Amgen, Bloomberg says 05/15/23 FTC looks to block Horizon Therapeutics deal with Amgen, Capitol Forum says AMGN Amgen $218.03 / +3.76 (+1.75%) 05/16/23 What You Missed On Wall Street On Tuesday 05/16/23 What You Missed On Wall Street This Morning 05/16/23 Fly Intel: Pre-market Movers 04/27/23 Fly Intel: After-Hours Movers 06/28/23 Biotech/Biopharma 06/28/23 Biotech/Biopharma AMGN Amgen $218.03 / +3.76 (+1.75%) 04/05/23 Early notable gainers among liquid option names on April 5th 02/17/23 Early notable gainers among liquid option names on February 17th 01/31/23 Amgen options imply 3.2% move in share price post-earnings
Hot Stocks	Bristol-Myers presents follow-up results from Phase 3 CheckMate -9LA trial » 08:45 06/04/23 06/04 08:45 06/04/23 08:45 BMY Bristol-Myers $65.66 / +0.98 (+1.52%) Bristol-Myers Squibb… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 7th, 08:45 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 06/03/23 Replimune presents data from Phase 1 trial of RP2 with nivolumab at ASCO 06/03/23 Replimune presents RP1 data from IGNYTE trial at ASCO 05/30/23 Bristol-Myers' repotrectinib application in lung cancer accepted by FDA 05/26/23 Bristol-Myers reports CHMP opinion recommending approval for Opdivo combination BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 05/01/23 Barclays Bristol-Myers price target lowered to $65 from $66 at Barclays 04/28/23 Credit Suisse Bristol-Myers price target lowered to $72 from $78 at Credit Suisse 04/21/23 BofA Bristol-Myers price target raised to $85 from $82 at BofA 04/20/23 H.C. Wainwright Legend Biotech price target raised to $77 from $66 at H.C. Wainwright BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 04/27/23 Bristol-Myers backs FY23 adjusted EPS view $7.95-$8.25, consensus $8.06 04/27/23 Bristol-Myers reports Q1 adjusted EPS $2.05, consensus $1.97 04/26/23 Notable companies reporting before tomorrow's open BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 01/04/23 Aurinia worth 'keeping closer eye on' after settlement, Dealreporter says BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 Fly Intel: Pre-market Movers 01/17/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology 07/27/23 Bristol-Myers - BMY 06/16/23 PDUFA Date for CAMZYOS 12/16/23 PDUFA Date for Abecma BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 03/10/23 Bristol Myers Squibb put volume heavy and directionally bearish 02/24/23 Bristol Myers Squibb put volume heavy and directionally bearish
Hot Stocks	ImmunoGen presents results Phase 3 confirmatory MIRASOL trial » 08:41 06/04/23 06/04 08:41 06/04/23 08:41 IMGN ImmunoGen $14.36 / +0.195 (+1.38%) ImmunoGen announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 7th, 08:41 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options IMGN ImmunoGen $14.36 / +0.195 (+1.38%) 05/10/23 Cerevel Therapeutics appoints Susan Altschuller as CFO 05/03/23 ImmunoGen reports 'positive' results from Phase 3 MIRASOL trial 04/28/23 ImmunoGen raises FY23 revenue excluding ELAHERE view to $45M-$50M 04/24/23 ImmunoGen names Isabel Kalofonos as Chief Commercial Officer IMGN ImmunoGen $14.36 / +0.195 (+1.38%) 05/03/23 Piper Sandler ImmunoGen upgraded to Overweight at Piper after 'overwhelmingly positive' data 05/03/23 H.C. Wainwright H.C. Wainwright reiterates Buy on ImmunoGen following MIRASOL 'homerun' 05/03/23 Piper Sandler ImmunoGen upgraded to Overweight from Neutral at Piper Sandler 05/03/23 Guggenheim ImmunoGen's MIRASOL trial results represent best-case scenario, says Guggenheim IMGN ImmunoGen $14.36 / +0.195 (+1.38%) 04/28/23 ImmunoGen reports Q1 EPS (16c), consensus (25c) 03/01/23 ImmunoGen sees FY23 revenue $30M-$35M, consensus $117.67M 03/01/23 ImmunoGen reports Q4 EPS (23c), consensus (30c) 05 May IMGN ImmunoGen $14.36 / +0.195 (+1.38%) 05/03/23 What You Missed On Wall Street On Wednesday 05/03/23 What You Missed On Wall Street This Morning 05/03/23 Fly Intel: Pre-market Movers 04/28/23 What You Missed On Wall Street On Friday 06/07/23 Global Healthcare Conference 06/14/23 ImmunoGen, Inc. IMGN ImmunoGen $14.36 / +0.195 (+1.38%) 05/19/23 ImmunoGen call volume above normal and directionally bullish 04/28/23 Unusually active option classes on open April 28th 03/01/23 Unusually active option classes on open March 1st 01/10/23 Unusually active option classes on open January 10th
Hot Stocks	Summit presents data for investigational bispecific antibody ivonescimab » 08:28 06/04/23 06/04 08:28 06/04/23 08:28 SMMT Summit Therapeutics $1.81 / +0.09 (+5.25%) Summit Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 7th, 08:28 Get Free Trial ShowHide Related Items >><< Company News On The Fly Options SMMT Summit Therapeutics $1.81 / +0.09 (+5.25%) 06/01/23 Summit Therapeutics: Ivonescimab updated data to be featured at ASCO 2023 05/09/23 Summit Therapeutics doses first patient in HARMONi study 05/03/23 Summit Therapeutics announces initial indications for clinical trials for SMT112 01/20/23 Summit Therapeutics closes deal with Akeso to in-license ivonescimab SMMT Summit Therapeutics $1.81 / +0.09 (+5.25%) 12/08/22 Biotech Alert: Searches spiking for these stocks today SMMT Summit Therapeutics $1.81 / +0.09 (+5.25%) 05/24/23 Unusually active option classes on open May 24th 03/15/23 Largest borrow rate increases among liquid names 03/08/23 Largest borrow rate increases among liquid names 01/09/23 Largest borrow rate increases among liquid names
Hot Stocks	AstraZeneca says TAGRISSO achieved 'unprecedent' survival in EGFRm » 08:24 06/04/23 06/04 08:24 06/04/23 08:24 AZN AstraZeneca $72.57 / -0.27 (-0.37%) AstraZeneca says… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 7th, 08:24 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AZN AstraZeneca $72.57 / -0.27 (-0.37%) 06/03/23 AstraZeneca interim analysis of DUO-O trial shows statistically significant PFS 06/02/23 AstraZeneca's IMFINZI plus chemo improved pathologic response in Phase III trial 06/02/23 AstraZeneca says Imfinzi plus chemotherapy showed clinical benefit in trial 06/01/23 AstraZeneca, Merck announce LYNPARZA + abiraterone approved for BRCAm cancer AZN AstraZeneca $72.57 / -0.27 (-0.37%) 05/26/23 Argus AstraZeneca price target lowered to $80 from $85 at Argus 05/09/23 Berenberg AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg 04/28/23 JPMorgan AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan 04/13/23 Argus AstraZeneca price target raised to $85 from $75 at Argus AZN AstraZeneca $72.57 / -0.27 (-0.37%) 04/27/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 04/27/23 AstraZeneca reports Q1 core EPS $1.92, consensus $1.07 02/09/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 02/09/23 AstraZeneca reports Q4 core EPS $1.38, consensus $1.35 AZN AstraZeneca $72.57 / -0.27 (-0.37%) 05/26/23 Health authorities to target next COVID shot to new strain, WSJ says 05/19/23 Astra China head says company seeks to 'love the Communist Party,' Reuters says 05/04/23 AstraZeneca chair says increasing CEO's pay wards of rivals, FT reports 04/06/23 GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says AZN AstraZeneca $72.57 / -0.27 (-0.37%) 04/11/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/05/23 What You Missed On Wall Street On Wednesday 04/05/23 What You Missed On Wall Street This Morning 02/09/23 What You Missed On Wall Street This Morning 06/05/23 Biotechnology--Dinner 12/22/23 PDUFA Date for Eplontersen AZN AstraZeneca $72.57 / -0.27 (-0.37%) 05/26/23 Unusually active option classes on open May 26th 05/18/23 Unusually active option classes on open May 18th 05/09/23 AstraZeneca put volume heavy and directionally bearish 04/27/23 Unusually active option classes on open April 27th
Hot Stocks	G1 Therapeutics presents data from Phase 2 study of trilaciclib in TNBC » 07:28 06/04/23 06/04 07:28 06/04/23 07:28 GTHX G1 Therapeutics $2.62 / +0.09 (+3.56%) G1 Therapeutics presented… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 7th, 07:28 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events GTHX G1 Therapeutics $2.62 / +0.09 (+3.56%) 05/22/23 G1 Therapeutics appoints Monica Thomas as Chief Compliance Officer 05/16/23 G1 confirms risk of myelosuppressive events for patients receiving chemotherapy 05/10/23 G1 Therapeutics announces new results from Phase 2 trial of trilaciclib 05/03/23 G1 Therapeutics sees FY23 COSELA net revenue $50M-$60M GTHX G1 Therapeutics $2.62 / +0.09 (+3.56%) 01/30/23 JPMorgan G1 Therapeutics upgraded to Neutral into data catalysts at JPMorgan 01/30/23 JPMorgan G1 Therapeutics upgraded to Neutral from Underweight at JPMorgan 01/04/23 EF Hutton G1 Therapeutics initiated with a Buy at EF Hutton 01/03/23 Needham G1 Therapeutics named as Top Pick, added to Conviction list at Needham GTHX G1 Therapeutics $2.62 / +0.09 (+3.56%) 05/03/23 G1 Therapeutics reports Q1 EPS (53c), consensus (64c) 03/01/23 G1 Therapeutics reports Q4 EPS (73c), consensus (84c) 18 Nov GTHX G1 Therapeutics $2.62 / +0.09 (+3.56%) 02/15/23 Biotech Alert: Searches spiking for these stocks today 02/13/23 What You Missed On Wall Street On Monday 02/13/23 What You Missed On Wall Street This Morning 06/15/23 G1 Therapeutics, Inc.
Periodicals	Saudi Arabia, some OPEC members clash over production quotas, WSJ reports » 06:37 06/04/23 06/04 06:37 06/04/23 06:37 BP BP $35.64 / +0.93 (+2.68%) , COP ConocoPhillips $102.36 / +3.04 (+3.06%) , SHEL Shell $58.25 / +1.16 (+2.03%) , TTE TotalEnergies $59.20 / +1.58 (+2.74%) , XOM Exxon Mobil $105.74 / +2.42 (+2.34%) , CVX Chevron $156.24 / +4.09 (+2.69%) Saudi Arabia and some… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 7th, 06:37 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options XOM SHEL CVX COP BP XOM Exxon Mobil $105.74 / +2.42 (+2.34%) 06/01/23 Par Pacific completes acquisition of Exxon Mobil Billings refinery 06/01/23 Nucor enters into carbon capture and storage agreement with Exxon Mobil 05/22/23 Chord Energy to acquire assets in the Williston Basin for $375M 05/02/23 TechnipFMC awarded large subsea contract for ExxonMobil Guyana's Uaru project SHEL Shell $58.25 / +1.16 (+2.03%) 05/25/23 TechnipFMC awarded significant contract by Shell for Dover development 05/04/23 Shell announces Q1 interim dividend of 28.75c 05/04/23 Shell sees FY23 cash capital expenditure $23B-$27B 05/04/23 Shell reports Q1 adjusted EPS $1.39, consensus $2.11 CVX Chevron $156.24 / +4.09 (+2.69%) 05/22/23 Chevron to acquire PDC Energy in $6.3B all-stock transaction 05/15/23 Berkshire Hathaway takes stake in Capital One, exits RH 05/15/23 Tiger Management adds Nvidia in Q1, sells out of Toast and Chevron 04/28/23 Chevron expects to repurchase $4.375B in shares in Q2 COP ConocoPhillips $102.36 / +3.04 (+3.06%) 05/26/23 ConocoPhillips to also pay contigent payments of up to $325M 05/26/23 ConocoPhillips buying remaining 50% interest in Surmont from TotalEnergies EP 05/26/23 ConocoPhillips to buy remaining 50% interest in Surmont for $3B 05/26/23 ConocoPhillips exercising preemption right to buy 50% interest in Surmont BP BP $35.64 / +0.93 (+2.68%) 05/31/23 BP selects Honeywell's Ecofining technology to support production of SAF 05/17/23 Justice Department announces $40M Clean Air Act settlement with BP 05/10/23 TravelCenters of America stockholders approve BP transaction 05/02/23 BP down 5% in pre-market after Q1 earnings, FY23 capex outlook update BP COP SHEL TTE XOM CVX BP BP $35.64 / +0.93 (+2.68%) 05/04/23 Credit Suisse BP price target lowered to 610 GBp from 630 GBp at Credit Suisse 05/04/23 Berenberg BP price target lowered to 560 GBp from 590 GBp at Berenberg 05/03/23 DZ Bank BP downgraded to Hold from Buy at DZ Bank 05/03/23 AlphaValue/Baader BP upgraded to Add from Sell at AlphaValue/Baader COP ConocoPhillips $102.36 / +3.04 (+3.06%) 05/19/23 Mizuho ConocoPhillips price target lowered to $126 from $128 at Mizuho 05/18/23 Piper Sandler ConocoPhillips price target raised to $149 from $140 at Piper Sandler 05/15/23 Morgan Stanley ConocoPhillips price target raised to $124 from $122 at Morgan Stanley 05/01/23 Goldman Sachs Exxon Mobil downgraded to Neutral from Buy at Goldman Sachs SHEL Shell $58.25 / +1.16 (+2.03%) 05/24/23 Citi Citi opens 'downside catalyst watch' on Shell into capital markets day 05/18/23 Piper Sandler Shell price target lowered to $75 from $77 at Piper Sandler 04/20/23 Piper Sandler Shell price target raised to $77 from $75 at Piper Sandler 04/19/23 JPMorgan Shell price target lowered to 2,950 GBp from 3,000 GBp at JPMorgan TTE TotalEnergies $59.20 / +1.58 (+2.74%) 05/19/23 Deutsche Bank TotalEnergies price target raised to EUR 59.80 from EUR 56.20 at Deutsche Bank 05/18/23 Piper Sandler TotalEnergies price target lowered to $68 from $69 at Piper Sandler 04/19/23 JPMorgan TotalEnergies price target lowered to EUR 69 from EUR 73 at JPMorgan 04/11/23 Redburn TotalEnergies upgraded to Neutral from Sell at Redburn XOM Exxon Mobil $105.74 / +2.42 (+2.34%) 06/01/23 RBC Capital Exxon Mobil downgraded to Sector Perform from Outperform at RBC Capital 05/19/23 Mizuho Exxon Mobil price target lowered to $130 from $147 at Mizuho 05/18/23 Piper Sandler Exxon Mobil price target raised to $145 from $134 at Piper Sandler 05/15/23 Jefferies Exxon Mobil price target lowered to $140 from $148 at Jefferies CVX Chevron $156.24 / +4.09 (+2.69%) 06/01/23 RBC Capital Chevron upgraded to Outperform from Sector Perform at RBC Capital 05/31/23 JPMorgan Chevron upgraded to Neutral from Underweight at JPMorgan 05/24/23 Mizuho Chevron price target raised to $202 from $196 at Mizuho 05/24/23 Mizuho PDC Energy downgraded to Neutral from Buy at Mizuho XOM TTE SHEL CVX COP BP XOM Exxon Mobil $105.74 / +2.42 (+2.34%) 04/28/23 Exxon Mobil reports Q1 adjusted EPS $2.83, consensus $2.59 04/27/23 Notable companies reporting before tomorrow's open 01/31/23 Exxon Mobil reports Q4 adjusted EPS $3.40, consensus $3.29 TTE TotalEnergies $59.20 / +1.58 (+2.74%) 02/08/23 TotalEnergies reports Q4 EPS $2.97, consensus $3.03 SHEL Shell $58.25 / +1.16 (+2.03%) 04/06/23 Shell sees Q1 corporate adjusted earnings loss of ($0.9B)-($1.2B) 02/02/23 Shell reports Q4 adjusted EPS $1.39 vs. 83c last year CVX Chevron $156.24 / +4.09 (+2.69%) 04/28/23 Chevron reports Q1 adjusted EPS $3.55, consensus $3.41 01/27/23 Chevron reports Q4 adjusted EPS $4.09, consensus $4.38 COP ConocoPhillips $102.36 / +3.04 (+3.06%) 05/04/23 ConocoPhillips reports Q1 EPS $2.38, consensus $2.10 05/03/23 Notable companies reporting before tomorrow's open 02/02/23 ConocoPhillips reports Q4 EPS $2.71, consensus $2.81 BP BP $35.64 / +0.93 (+2.68%) 05/02/23 BP reports Q1 EPS $1.66, consensus $1.40 02/07/23 BP reports Q4 EPS $1.59, consensus $1.67 XOM TTE SHEL CVX COP BP XOM Exxon Mobil $105.74 / +2.42 (+2.34%) 06/02/23 Exxon, Chevron in advanced talks to drill for gas in Algeria, WSJ reports 05/26/23 Four bidders compete to buy Exxon LNG terminal stake in Italy, Reuters reports TTE TotalEnergies $59.20 / +1.58 (+2.74%) 04/13/23 TotalEnergies weighing bid for Neptune Energy, Bloomberg says 04/13/23 TotalEnergies weighing bid for $5B E&P company Neptune, Bloomberg says SHEL Shell $58.25 / +1.16 (+2.03%) 05/17/23 Shell planning sale of French floating wind developer Eolfi, Bloomberg says 05/17/23 Shell plans sale of French floating wind power unit EOLFI, Bloomberg says CVX Chevron $156.24 / +4.09 (+2.69%) 04/24/23 State-law climate suits against oil companies to proceed, WSJ reports COP ConocoPhillips $102.36 / +3.04 (+3.06%) 04/06/23 Buyout firm EnCap ponders nearly $3B of Permian asset sales, Reuters reports 04/02/23 OPEC+ announces surprise oil production cut, Bloomberg says BP BP $35.64 / +0.93 (+2.68%) 06/02/23 OPEC+ unlikely to agree on further oil supply reductions Sunday, Reuters says 05/21/23 IEA expects no impact on oil supply by price cap enforcement, Reuters says 05/05/23 BP explores sale of two firms owned by venture unit, Sky reports 04/25/23 BP, Linde in talks over natgas supply for blue hydrogen project, Bloomberg says XOM TTE SHEL COP BP XOM Exxon Mobil $105.74 / +2.42 (+2.34%) 06/02/23 What You Missed On Wall Street On Friday 06/02/23 What You Missed On Wall Street This Morning 06/01/23 What You Missed On Wall Street On Thursday 06/01/23 What You Missed On Wall Street This Morning TTE TotalEnergies $59.20 / +1.58 (+2.74%) 04/13/23 What You Missed On Wall Street On Thursday 04/13/23 What You Missed On Wall Street This Morning 04/04/23 What You Missed On Wall Street On Tuesday SHEL Shell $58.25 / +1.16 (+2.03%) 04/06/23 Fly Intel: Pre-market Movers 02/28/23 What You Missed On Wall Street On Tuesday COP ConocoPhillips $102.36 / +3.04 (+3.06%) 05/26/23 What You Missed On Wall Street On Friday 03/13/23 What You Missed On Wall Street This Morning BP BP $35.64 / +0.93 (+2.68%) 04/24/23 Fly Intel: Pre-market Movers 04/03/23 What You Missed On Wall Street On Monday 04/03/23 What You Missed On Wall Street This Morning 03/23/23 What You Missed On Wall Street This Morning XOM TTE SHEL CVX COP BP XOM Exxon Mobil $105.74 / +2.42 (+2.34%) 04/28/23 Unusually active option classes on open April 28th 12/07/22 Exxon Mobil put buyer realizes 12% same-day gains TTE TotalEnergies $59.20 / +1.58 (+2.74%) 04/21/23 Largest borrow rate increases among liquid names SHEL Shell $58.25 / +1.16 (+2.03%) 05/31/23 Shell PLC put volume heavy and directionally bearish 05/25/23 Shell PLC put volume heavy and directionally bearish 05/24/23 Shell PLC put volume heavy and directionally bearish 03/17/23 Shell PLC put volume heavy and directionally bearish CVX Chevron $156.24 / +4.09 (+2.69%) 05/10/23 Chevron call volume above normal and directionally bullish 03/15/23 Chevron put volume heavy and directionally bearish 03/10/23 Early notable gainers among liquid option names on March 10th 01/27/23 Unusually active option classes on open January 27th COP ConocoPhillips $102.36 / +3.04 (+3.06%) 05/16/23 ConocoPhillips put volume heavy and directionally bearish 04/05/23 ConocoPhillips call volume above normal and directionally bullish 04/03/23 Early notable gainers among liquid option names on April 3rd 04/03/23 Unusually active option classes on open April 3rd BP BP $35.64 / +0.93 (+2.68%) 06/02/23 Unusually active option classes on open June 2nd 05/04/23 BP call volume above normal and directionally bullish 05/04/23 Unusually active option classes on open May 4th 05/02/23 Unusually active option classes on open May 2nd
Periodicals	Bank stocks too beaten down, JPMorgan among those to buy now, Barron's says » 06:29 06/04/23 06/04 06:29 06/04/23 06:29 JPM JPMorgan $140.47 / +2.9 (+2.11%) , CFG Citizens Financial $27.79 / +1.41 (+5.34%) The past three months saw… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 7th, 06:29 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JPM CFG JPM JPMorgan $140.47 / +2.9 (+2.11%) 06/01/23 J.P. Morgan launches Payments Partner Network powered by Salesforce Cloud 05/23/23 Climb Global signs $50M credit facility with JPMorgan Chase 05/22/23 Tegna announces $300M ASR agreement with JPMorgan Chase Bank 05/22/23 Dimon says 'everybody should be prepared for higher rates from here' CFG Citizens Financial $27.79 / +1.41 (+5.34%) 05/23/23 Citizens Bank to pay $9M penalty to CFPB for unlawful credit card servicing 05/23/23 Citizens Financial comments on CFPB settlement 05/11/23 PacWest Bancorp down 21% after detailing deposit losses in early May 05/03/23 Citizens Bank raises prime lending rate to 8.25% from 8% JPM CFG JPM JPMorgan $140.47 / +2.9 (+2.11%) 05/23/23 Morgan Stanley JPMorgan price target raised to $160 from $157 at Morgan Stanley 05/15/23 Jefferies JPMorgan price target lowered to $149 from $152 at Jefferies 05/12/23 Citi State Street, BNY Mellon hurt most from FDIC proposal, says Citi 05/12/23 Evercore ISI JPMorgan price target lowered to $151 from $155 at Evercore ISI CFG Citizens Financial $27.79 / +1.41 (+5.34%) 04/20/23 RBC Capital Citizens Financial price target raised to $52 from $48 at RBC Capital 04/20/23 DA Davidson Citizens Financial price target lowered to $37 from $40 at DA Davidson 04/20/23 Credit Suisse Citizens Financial price target lowered to $35 from $44 at Credit Suisse JPM CFG JPM JPMorgan $140.47 / +2.9 (+2.11%) 05/22/23 JPMorgan now sees FY NII ex-Markets $84B due to First Republic 04/14/23 JPMorgan reports Q1 EPS $4.10, consensus $3.41 04/13/23 Notable companies reporting before tomorrow's open 01/13/23 JPMorgan reports Q4 EPS $3.57, consensus $3.07 CFG Citizens Financial $27.79 / +1.41 (+5.34%) 04/19/23 Citizens Financial reports Q1 underlying EPS $1.10, consensus $1.13 04/19/23 Citizens Financial reports Q1 underlying EPS $1.10, consensus $1.13 04/18/23 Notable companies reporting before tomorrow's open JPM CFG JPM JPMorgan $140.47 / +2.9 (+2.11%) 06/01/23 JPMorgan plans closure of 21 First Republic branches, Reuters reports 06/01/23 JPMorgan CEO Dimon denies contact with Epstein, NY Times reports 05/26/23 JPMorgan cut 500 positions this week, CNBC reports 05/26/23 JPMorgan CEO set to be deposed in Epstein suits, CNBC reports CFG Citizens Financial $27.79 / +1.41 (+5.34%) 04/30/23 First Republic deal expected by Sunday night, Reuters reports 03/29/23 Citizens Financial investigated in MA for sales of savings product, WSJ reports 03/24/23 Citizens Financial working on bid for SVB Private, Reuters reports JPM CFG JPM JPMorgan $140.47 / +2.9 (+2.11%) 06/01/23 What You Missed On Wall Street This Morning 05/26/23 What You Missed On Wall Street On Friday 05/26/23 What You Missed On Wall Street This Morning 05/25/23 What You Missed On Wall Street On Thursday CFG Citizens Financial $27.79 / +1.41 (+5.34%) 04/19/23 What You Missed On Wall Street On Wednesday 04/19/23 What You Missed On Wall Street This Morning 04/19/23 Fly Intel: Pre-market Movers 01/17/23 What You Missed On Wall Street On Tuesday 07/14/23 JPMorgan - JPM 07/19/23 Citizens Financial - CFG JPM CFG JPM JPMorgan $140.47 / +2.9 (+2.11%) 04/14/23 Early notable gainers among liquid option names on April 14th 04/14/23 Unusually active option classes on open April 14th 03/10/23 Unusually active option classes on open March 10th 01/19/23 JPMorgan put buyer realizes 24% same-day gains CFG Citizens Financial $27.79 / +1.41 (+5.34%) 05/31/23 Citizens Financial put volume heavy and directionally bearish 05/02/23 Citizens Financial put volume heavy and directionally bearish 04/28/23 Citizens Financial call volume above normal and directionally bullish 03/31/23 Citizens Financial call volume above normal and directionally bullish
Periodicals	Ride not over for Eaton stock, Barron's says » 06:25 06/04/23 06/04 06:25 06/04/23 06:25 ETN Eaton $186.48 / +7.435 (+4.15%) A year ago, the backlog… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 7th, 06:25 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly ETN Eaton $186.48 / +7.435 (+4.15%) 05/01/23 BAE Systems, Eaton collaborate on electric drive solutions 04/24/23 Eaton acquires 49% stake in Jiangsu Ryan Electrical Co. 03/28/23 Waters Eaton appoints Fearon to board of directors 03/24/23 Charge Enterprises, Eaton announce strategic collaboration ETN Eaton $186.48 / +7.435 (+4.15%) 05/11/23 UBS Eaton price target raised to $210 from $205 at UBS 05/09/23 Evercore ISI Eaton price target raised to $221 from $201 at Evercore ISI 05/03/23 Mizuho Eaton price target raised to $180 from $168 at Mizuho 05/03/23 Barclays Eaton price target raised to $159 from $145 at Barclays ETN Eaton $186.48 / +7.435 (+4.15%) 05/02/23 Eaton raises FY23 adjusted EPS view to $8.30-$8.50 from $8.04-$8.44 05/02/23 Eaton sees Q2 adjusted EPS $2.04-$2.14, consensus $2.05 05/02/23 Eaton reports Q1 adjusted EPS $1.88, consensus $1.78 02/08/23 Eaton sees Q1 adjusted EPS $1.72-$1.82, consensus $1.80 ETN Eaton $186.48 / +7.435 (+4.15%) 12/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations

Periodicals	IBM hiding in plain sight, paying big dividend, Barron's says » 06:21 06/04/23 06/04 06:21 06/04/23 06:21 IBM IBM $132.37 / +2.5698 (+1.98%) IBM is one of the most… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 7th, 06:21 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options IBM IBM $132.37 / +2.5698 (+1.98%) 05/24/23 Diageo announces partnership with SAP and IBM 05/16/23 IBM to acquire Polar Security; terms not disclosed 05/09/23 IBM unveils new AI and data platform Watsonx to enhance impact of AI 04/25/23 IBM, Noname Security collaborate to deliver advanced API security offerings IBM IBM $132.37 / +2.5698 (+1.98%) 05/12/23 DA Davidson tech/software analysts to hold analyst/industry conference call 04/20/23 TD Cowen SentinelOne fits criteria for strategic interest, says TD Cowen 04/20/23 BMO Capital IBM price target lowered to $145 from $155 at BMO Capital 04/20/23 Evercore ISI IBM price target lowered to $140 from $150 at Evercore ISI IBM IBM $132.37 / +2.5698 (+1.98%) 04/19/23 IBM sees FY23 constant currency revenue growth 3%-5%, consensus $62.69B 04/19/23 IBM reports Q1 adjusted EPS $1.36, consensus $1.26 04/19/23 Notable companies reporting after market close 01/25/23 IBM sees FY23 revenue growth consistent with mid-single digit model IBM IBM $132.37 / +2.5698 (+1.98%) 05/23/23 White House wants workers opinion on employers use of AI, Reuters reports 05/02/23 IBM to slow down, stop back-office hiring, Bloomberg reports 04/12/23 IBM looks into sale of weather business, WSJ reports 02/14/23 IBM sues former Thai executive for $470,000 in bonus awards, Bloomberg reports IBM IBM $132.37 / +2.5698 (+1.98%) 05/02/23 What You Missed On Wall Street On Tuesday 05/02/23 What You Missed On Wall Street This Morning 04/20/23 What You Missed On Wall Street On Thursday 04/20/23 What You Missed On Wall Street This Morning IBM IBM $132.37 / +2.5698 (+1.98%) 05/31/23 Unusually active option classes on open May 31st 04/19/23 IBM options imply 3.7% move in share price post-earnings 03/30/23 Unusually active option classes on open March 30th 03/28/23 Unusual call flow in option market yesterday
Periodicals	Twitter loses another senior executive in charge of content, safety, WSJ says » 17:46 06/03/23 06/03 17:46 06/03/23 17:46 TWTR Twitter $53.71 / + (+0.00%) A second senior executive… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:46 Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly TWTR Twitter $53.71 / + (+0.00%) 05/25/23 Ford, Tesla CEOs to host Twitter Spaces chat on accelerating EV adoption 05/18/23 Twitter now lets Blue subscribers upload two-hour videos 05/18/23 Supreme Court declines to address Section 230 shield in Google ruling 05/12/23 Musk says 'bringing on Linda allows me to devote more time to Tesla' TWTR Twitter $53.71 / + (+0.00%) 05/12/23 Wedbush New Twitter CEO positive for Tesla shares, says Wedbush 02/03/23 Morgan Stanley Sprout, Sprinklr pacts minimize impact of Twitter decision, says Morgan Stanley 12/19/22 Wedbush End of Twitter CEO reign would be 'major positive' for Tesla, says Wedbush 11/23/22 Morgan Stanley Morgan Stanley wonders if 'value opportunity emerging' in Tesla after selloff TWTR Twitter $53.71 / + (+0.00%) 05/23/23 DeSantis will launch his presidential bid with Elon Musk, NBC News reports 05/19/23 Meta readying Instagram text-based app to compete with Twitter, Bloomberg says 05/19/23 Meta readying Instagram text-based app to compete with Twitter, Bloomberg says 05/19/23 Meta preparing Twitter competitor for release this summer, Bloomberg says TWTR Twitter $53.71 / + (+0.00%) 05/24/23 #SocialStocks: Meta fined EUR 1.2B in Ireland for infringing on data laws 05/19/23 What You Missed On Wall Street On Friday 05/19/23 What You Missed On Wall Street This Morning 05/17/23 #SocialStocks: Tech companies seek employees abroad after hiring freeze
Hot Stocks	Janssen Pharmaceuticals announces updated data from Phase 2 TRiMM-2 study » 17:39 06/03/23 06/03 17:39 06/03/23 17:39 JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) The Janssen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:39 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/03/23 Janssen presents analysis of infections, parameters in Monumen-TAL1 study 06/03/23 Janssen Pharmaceuticals announced results from Phase 1/2 MonumenTAL-1 study 06/03/23 Janssen announces results from Phase 1b RedirecTT-1 study 05/31/23 Janssen says Tremfya showed 'sustainable improvements' in psoriatic arthritis JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/30/23 RBC Capital Kenvue initiated with an Outperform at RBC Capital 05/30/23 Citi Johnson & Johnson resumed with a Buy at Citi 05/30/23 JPMorgan JPMorgan starts Kenvue with Overweight on 'resilient growth' 05/30/23 Goldman Sachs Kenvue initiated with a Neutral at Goldman Sachs JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65 04/18/23 Johnson & Johnson reports Q1 adjusted EPS $2.68, consensus $2.51 04/17/23 Notable companies reporting before tomorrow's open 02/28/23 Fate Therapeutics reports Q4 EPS (58c), consensus (86c) JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/26/23 Health authorities to target next COVID shot to new strain, WSJ says 05/23/23 Amgen, J&J settle patent lawsuit over Stelara biosimilar, Reuters reports 05/10/23 New suitors showing interest in ShockWave Medical, Street Insider says 05/03/23 Johnson & Johnson's Kenvue to price at $22 per share, Bloomberg says JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/02/23 Buy/Sell: Wall Street's top 10 stock calls this week 05/30/23 What You Missed On Wall Street On Tuesday 05/30/23 What You Missed On Wall Street This Morning 05/30/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Unusually active option classes on open April 18th 04/06/23 Unusually active option classes on open April 6th 04/05/23 Early notable gainers among liquid option names on April 5th 04/05/23 Unusually active option classes on open April 5th
Hot Stocks	Janssen presents analysis of infections, parameters in Monumen-TAL1 study » 17:39 06/03/23 06/03 17:39 06/03/23 17:39 JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) The Janssen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:39 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/03/23 Janssen Pharmaceuticals announced results from Phase 1/2 MonumenTAL-1 study 06/03/23 Janssen announces results from Phase 1b RedirecTT-1 study 05/31/23 Janssen says Tremfya showed 'sustainable improvements' in psoriatic arthritis 05/25/23 Legend: Type II variation application submitted to EMA for CARVYKTI JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/30/23 RBC Capital Kenvue initiated with an Outperform at RBC Capital 05/30/23 Citi Johnson & Johnson resumed with a Buy at Citi 05/30/23 JPMorgan JPMorgan starts Kenvue with Overweight on 'resilient growth' 05/30/23 Goldman Sachs Kenvue initiated with a Neutral at Goldman Sachs JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65 04/18/23 Johnson & Johnson reports Q1 adjusted EPS $2.68, consensus $2.51 04/17/23 Notable companies reporting before tomorrow's open 02/28/23 Fate Therapeutics reports Q4 EPS (58c), consensus (86c) JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/26/23 Health authorities to target next COVID shot to new strain, WSJ says 05/23/23 Amgen, J&J settle patent lawsuit over Stelara biosimilar, Reuters reports 05/10/23 New suitors showing interest in ShockWave Medical, Street Insider says 05/03/23 Johnson & Johnson's Kenvue to price at $22 per share, Bloomberg says JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/02/23 Buy/Sell: Wall Street's top 10 stock calls this week 05/30/23 What You Missed On Wall Street On Tuesday 05/30/23 What You Missed On Wall Street This Morning 05/30/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Unusually active option classes on open April 18th 04/06/23 Unusually active option classes on open April 6th 04/05/23 Early notable gainers among liquid option names on April 5th 04/05/23 Unusually active option classes on open April 5th
Hot Stocks	Janssen Pharmaceuticals announced results from Phase 1/2 MonumenTAL-1 study » 17:39 06/03/23 06/03 17:39 06/03/23 17:39 JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) The Janssen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:39 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/03/23 Janssen announces results from Phase 1b RedirecTT-1 study 05/31/23 Janssen says Tremfya showed 'sustainable improvements' in psoriatic arthritis 05/25/23 Legend: Type II variation application submitted to EMA for CARVYKTI 05/25/23 Bristol-Myers granted FDA Fast Track Designation for 3 milvexian indications JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/30/23 RBC Capital Kenvue initiated with an Outperform at RBC Capital 05/30/23 Citi Johnson & Johnson resumed with a Buy at Citi 05/30/23 JPMorgan JPMorgan starts Kenvue with Overweight on 'resilient growth' 05/30/23 Goldman Sachs Kenvue initiated with a Neutral at Goldman Sachs JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65 04/18/23 Johnson & Johnson reports Q1 adjusted EPS $2.68, consensus $2.51 04/17/23 Notable companies reporting before tomorrow's open 02/28/23 Fate Therapeutics reports Q4 EPS (58c), consensus (86c) JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/26/23 Health authorities to target next COVID shot to new strain, WSJ says 05/23/23 Amgen, J&J settle patent lawsuit over Stelara biosimilar, Reuters reports 05/10/23 New suitors showing interest in ShockWave Medical, Street Insider says 05/03/23 Johnson & Johnson's Kenvue to price at $22 per share, Bloomberg says JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/02/23 Buy/Sell: Wall Street's top 10 stock calls this week 05/30/23 What You Missed On Wall Street On Tuesday 05/30/23 What You Missed On Wall Street This Morning 05/30/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Unusually active option classes on open April 18th 04/06/23 Unusually active option classes on open April 6th 04/05/23 Early notable gainers among liquid option names on April 5th 04/05/23 Unusually active option classes on open April 5th
Hot Stocks	Replimune Group announces 3 trial-in-progress abstracts at ASCO » 17:26 06/03/23 06/03 17:26 06/03/23 17:26 REPL Replimune Group $19.00 / +0.55 (+2.98%) Additional Abstracts… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:26 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly REPL Replimune Group $19.00 / +0.55 (+2.98%) 06/03/23 Replimune presents data from Phase 1 trial of RP2 with nivolumab at ASCO 06/03/23 Replimune presents RP1 data from IGNYTE trial at ASCO 05/18/23 Replimune Group enters transition, separation agreement with CFO Jean Franchi 05/18/23 Replimune Group expects cash to fund operations into 2H25 REPL Replimune Group $19.00 / +0.55 (+2.98%) 04/17/23 Piper Sandler Replimune Group assumed with an Overweight at Piper Sandler 02/10/23 H.C. Wainwright Replimune Group price target raised to $50 from $48 at H.C. Wainwright 01/04/23 EF Hutton Replimune Group initiated with a Buy at EF Hutton 01/02/23 Barclays Barclays views GSK acquisition interest as positive for oncology stocks REPL Replimune Group $19.00 / +0.55 (+2.98%) 05/18/23 Replimune Group reports 2023 EPS ($2.99), consensus ($2.85) 02/09/23 Replimune Group reports Q3 EPS (69c), consensus (75c) 09 Dec REPL Replimune Group $19.00 / +0.55 (+2.98%) 12/09/22 Biotech Alert: Searches spiking for these stocks today
Hot Stocks	Replimune presents data from Phase 1 trial of RP2 with nivolumab at ASCO » 17:26 06/03/23 06/03 17:26 06/03/23 17:26 REPL Replimune Group $19.00 / +0.55 (+2.98%) , BMY Bristol-Myers $65.66 / +0.98 (+1.52%) Replimune Group (REPL)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:26 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 06/03/23 Replimune presents RP1 data from IGNYTE trial at ASCO 05/18/23 Replimune Group enters transition, separation agreement with CFO Jean Franchi 05/18/23 Replimune Group expects cash to fund operations into 2H25 01/04/23 Replimune Group announces inducement grants under Nasdaq listing rule BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 05/30/23 Bristol-Myers' repotrectinib application in lung cancer accepted by FDA 05/26/23 Bristol-Myers reports CHMP opinion recommending approval for Opdivo combination 05/25/23 Bristol-Myers to present first results from Phase 3 COMMANDS study of Reblozyl REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 04/17/23 Piper Sandler Replimune Group assumed with an Overweight at Piper Sandler 02/10/23 H.C. Wainwright Replimune Group price target raised to $50 from $48 at H.C. Wainwright 01/04/23 EF Hutton Replimune Group initiated with a Buy at EF Hutton 01/02/23 Barclays Barclays views GSK acquisition interest as positive for oncology stocks BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 05/01/23 Barclays Bristol-Myers price target lowered to $65 from $66 at Barclays 04/28/23 Credit Suisse Bristol-Myers price target lowered to $72 from $78 at Credit Suisse 04/21/23 BofA Bristol-Myers price target raised to $85 from $82 at BofA 04/20/23 H.C. Wainwright Legend Biotech price target raised to $77 from $66 at H.C. Wainwright REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 05/18/23 Replimune Group reports 2023 EPS ($2.99), consensus ($2.85) 02/09/23 Replimune Group reports Q3 EPS (69c), consensus (75c) BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 04/27/23 Bristol-Myers backs FY23 adjusted EPS view $7.95-$8.25, consensus $8.06 04/27/23 Bristol-Myers reports Q1 adjusted EPS $2.05, consensus $1.97 04/26/23 Notable companies reporting before tomorrow's open 09 Dec BMY BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 01/04/23 Aurinia worth 'keeping closer eye on' after settlement, Dealreporter says REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 12/09/22 Biotech Alert: Searches spiking for these stocks today BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 Fly Intel: Pre-market Movers 01/17/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology 07/27/23 Bristol-Myers - BMY 06/16/23 PDUFA Date for CAMZYOS 12/16/23 PDUFA Date for Abecma BMY BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 03/10/23 Bristol Myers Squibb put volume heavy and directionally bearish 02/24/23 Bristol Myers Squibb put volume heavy and directionally bearish
Hot Stocks	Replimune presents RP1 data from IGNYTE trial at ASCO » 17:26 06/03/23 06/03 17:26 06/03/23 17:26 REPL Replimune Group $19.00 / +0.55 (+2.98%) , BMY Bristol-Myers $65.66 / +0.98 (+1.52%) Replimune (REPL)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:26 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 05/18/23 Replimune Group enters transition, separation agreement with CFO Jean Franchi 05/18/23 Replimune Group expects cash to fund operations into 2H25 01/04/23 Replimune Group announces inducement grants under Nasdaq listing rule 01/04/23 Replimune Group appoints Chris Sarchi as CCO, Sushil Patel as CSO BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 05/30/23 Bristol-Myers' repotrectinib application in lung cancer accepted by FDA 05/26/23 Bristol-Myers reports CHMP opinion recommending approval for Opdivo combination 05/25/23 Bristol-Myers to present first results from Phase 3 COMMANDS study of Reblozyl 05/25/23 Bristol-Myers says Breyanzi first and only CAR-T to deliver efficacy in CLL/SLL REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 04/17/23 Piper Sandler Replimune Group assumed with an Overweight at Piper Sandler 02/10/23 H.C. Wainwright Replimune Group price target raised to $50 from $48 at H.C. Wainwright 01/04/23 EF Hutton Replimune Group initiated with a Buy at EF Hutton 01/02/23 Barclays Barclays views GSK acquisition interest as positive for oncology stocks BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 05/01/23 Barclays Bristol-Myers price target lowered to $65 from $66 at Barclays 04/28/23 Credit Suisse Bristol-Myers price target lowered to $72 from $78 at Credit Suisse 04/21/23 BofA Bristol-Myers price target raised to $85 from $82 at BofA 04/20/23 H.C. Wainwright Legend Biotech price target raised to $77 from $66 at H.C. Wainwright REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 05/18/23 Replimune Group reports 2023 EPS ($2.99), consensus ($2.85) 02/09/23 Replimune Group reports Q3 EPS (69c), consensus (75c) BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 04/27/23 Bristol-Myers backs FY23 adjusted EPS view $7.95-$8.25, consensus $8.06 04/27/23 Bristol-Myers reports Q1 adjusted EPS $2.05, consensus $1.97 04/26/23 Notable companies reporting before tomorrow's open 09 Dec BMY BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 01/04/23 Aurinia worth 'keeping closer eye on' after settlement, Dealreporter says REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 12/09/22 Biotech Alert: Searches spiking for these stocks today BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 Fly Intel: Pre-market Movers 01/17/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology 07/27/23 Bristol-Myers - BMY 06/16/23 PDUFA Date for CAMZYOS 12/16/23 PDUFA Date for Abecma BMY BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 03/10/23 Bristol Myers Squibb put volume heavy and directionally bearish 02/24/23 Bristol Myers Squibb put volume heavy and directionally bearish
Conference/Events	BTIG healthcare analysts to hold a reception » 17:25 06/03/23 06/03 17:25 06/03/23 17:25 Healthcare Analysts hold… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:25 Get Free Trial
Hot Stocks	Janssen announces results from Phase 1b RedirecTT-1 study » 17:18 06/03/23 06/03 17:18 06/03/23 17:18 JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) The Janssen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:18 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/31/23 Janssen says Tremfya showed 'sustainable improvements' in psoriatic arthritis 05/25/23 Legend: Type II variation application submitted to EMA for CARVYKTI 05/25/23 Bristol-Myers granted FDA Fast Track Designation for 3 milvexian indications 05/12/23 Protagonist and Janssen report data from preclinical studies of JNJ-2113 JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/30/23 RBC Capital Kenvue initiated with an Outperform at RBC Capital 05/30/23 Citi Johnson & Johnson resumed with a Buy at Citi 05/30/23 JPMorgan JPMorgan starts Kenvue with Overweight on 'resilient growth' 05/30/23 Goldman Sachs Kenvue initiated with a Neutral at Goldman Sachs JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65 04/18/23 Johnson & Johnson reports Q1 adjusted EPS $2.68, consensus $2.51 04/17/23 Notable companies reporting before tomorrow's open 02/28/23 Fate Therapeutics reports Q4 EPS (58c), consensus (86c) JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/26/23 Health authorities to target next COVID shot to new strain, WSJ says 05/23/23 Amgen, J&J settle patent lawsuit over Stelara biosimilar, Reuters reports 05/10/23 New suitors showing interest in ShockWave Medical, Street Insider says 05/03/23 Johnson & Johnson's Kenvue to price at $22 per share, Bloomberg says JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/02/23 Buy/Sell: Wall Street's top 10 stock calls this week 05/30/23 What You Missed On Wall Street On Tuesday 05/30/23 What You Missed On Wall Street This Morning 05/30/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Unusually active option classes on open April 18th 04/06/23 Unusually active option classes on open April 6th 04/05/23 Early notable gainers among liquid option names on April 5th 04/05/23 Unusually active option classes on open April 5th

Hot Stocks	Evaxion's trial of EVX-01 met its primary endpoints of safety, tolerability » 17:09 06/03/23 06/03 17:09 06/03/23 17:09 EVAX Evaxion Biotech $1.48 / + (+0.00%) Evaxion Biotech presented… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:09 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly EVAX Evaxion Biotech $1.48 / + (+0.00%) 05/25/23 Evaxion Biotech unveils technology to boost effect of DNA and mRNA vaccines 05/25/23 Evaxion Biotech to present Phase 1 data for personalized cancer vaccine 04/18/23 Evaxion Biotech announces promising data for DNA-based cancer immunotherapy 03/28/23 Evaxion announces increased focus on strategy around core AI capabilities EVAX Evaxion Biotech $1.48 / + (+0.00%) 03/31/23 Lake Street Evaxion Biotech price target lowered to $7 from $18 at Lake Street 11/17/22 Oppenheimer Evaxion Biotech price target lowered to $11 from $16 at Oppenheimer 07/18/22 Oppenheimer Evaxion Biotech assumed with an Outperform at Oppenheimer EVAX Evaxion Biotech $1.48 / + (+0.00%) 05/31/23 Evaxion Biotech reports Q1 EPS (24c) vs (25c) last year 04/27/23 Evaxion Biotech reports Q4 EPS (29c) vs (39c) last year EVAX Evaxion Biotech $1.48 / + (+0.00%) 01/03/23 What You Missed On Wall Street This Morning 01/03/23 Fly Intel: Pre-market Movers
Hot Stocks	Gracell presents long-term follow up data from study evaluating GC012F » 17:07 06/03/23 06/03 17:07 06/03/23 17:07 GRCL Gracell $3.05 / +0.09 (+3.04%) Gracell Biotechnologies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:07 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings GRCL Gracell $3.05 / +0.09 (+3.04%) 05/15/23 Gracell to host KOL webinar on Multiple Myeloma 05/15/23 Gracell begins study of GC012F in Lupus Erythematosus 03/13/23 Gracell sees cash runway to the end of 2024 02/13/23 Gracell: China's NMPA clears IND application for GC012F GRCL Gracell $3.05 / +0.09 (+3.04%) 03/27/23 Wells Fargo Gracell assumed with an Overweight at Wells Fargo 12/08/22 H.C. Wainwright Gracell initiated with a Buy at H.C. Wainwright 09/22/22 Citi Gracell initiated with a Buy at Citi 08/18/22 Wells Fargo Gracell assumed with an Overweight at Wells Fargo GRCL Gracell $3.05 / +0.09 (+3.04%) 05/15/23 Gracell reports Q1 EPS (RMB 0.45) vs (RMB 0.47) last year 03/13/23 Gracell reports Q4 EPS (6c), consensus (13c)
Hot Stocks	Sutro Biopharma announces results from Phase 1 dose-expansion study of luvelta » 17:02 06/03/23 06/03 17:02 06/03/23 17:02 STRO Sutro Biopharma $4.71 / +0.255 (+5.72%) Sutro Biopharma announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:02 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events STRO Sutro Biopharma $4.71 / +0.255 (+5.72%) 02/28/23 Sutro Biopharma appoints Borgman as Chief Medical Officer 12/20/22 Sutro Biopharma, Vaxcyte in development option grant deal for cell-free extract 12/07/22 Sutro Biopharma pediatric acute myeloid leukemia treatment granted orphan status STRO Sutro Biopharma $4.71 / +0.255 (+5.72%) 04/03/23 JMP Securities Sutro Biopharma price target lowered to $17 from $20 at JMP Securities 03/31/23 H.C. Wainwright Sutro Biopharma price target lowered to $16 from $20 at H.C. Wainwright 03/20/23 Wells Fargo Sutro transferred with Equal Weight from Overweight at Wells Fargo 01/13/23 Truist Sutro Biopharma price target raised to $25 from $21 at Truist STRO Sutro Biopharma $4.71 / +0.255 (+5.72%) 05/15/23 Sutro Biopharma reports Q1 EPS (85c), consensus (81c) 06/08/23 Sutro Biopharma, Inc.
Hot Stocks	Equitrans Midstream's Mountain Valley Pipeline to proceed » 16:58 06/03/23 06/03 16:58 06/03/23 16:58 ETRN Equitrans Midstream $9.08 / +0.24 (+2.71%) On June 3, 2023, the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 16:58 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ETRN Equitrans Midstream $9.08 / +0.24 (+2.71%) 05/30/23 Equitrans Midstream rises 34.2% 05/30/23 Equitrans Midstream rises 40.4% 05/30/23 Equitrans Midstream rises 44.7% ETRN Equitrans Midstream $9.08 / +0.24 (+2.71%) 06/01/23 Wolfe Research Equitrans Midstream upgraded to Outperform from Peer Perform at Wolfe Research 05/30/23 RBC Capital Equitrans Midstream upgraded to Outperform from Sector Perform at RBC Capital 04/21/23 Raymond James Equitrans Midstream initiated with a Market Perform at Raymond James 04/10/23 Barclays Equitrans Midstream price target lowered to $6 from $8 at Barclays ETRN Equitrans Midstream $9.08 / +0.24 (+2.71%) 05/02/23 Equitrans Midstream reports Q1 adjusted EPS 22c, consensus 15c 02/21/23 Equitrans Midstream sees FY23 adjusted EBITDA $1.06B-$1.14B 02/21/23 Equitrans Midstream sees Q1 adjusted EBITDA $270M-$290M 02/21/23 Equitrans Midstream sees Q1 adjusted EBITDA $270M-$290M ETRN Equitrans Midstream $9.08 / +0.24 (+2.71%) 05/30/23 What You Missed On Wall Street On Tuesday 05/30/23 What You Missed On Wall Street This Morning ETRN Equitrans Midstream $9.08 / +0.24 (+2.71%) 05/30/23 Unusually active option classes on open May 30th 05/26/23 Equitrans Midstream call volume above normal and directionally bullish
Hot Stocks	Cogent Biosciences announces data from ongoing Phase 3 PEAK trial » 16:56 06/03/23 06/03 16:56 06/03/23 16:56 COGT Cogent Biosciences $12.97 / +0.245 (+1.93%) Cogent Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 16:56 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events COGT Cogent Biosciences $12.97 / +0.245 (+1.93%) 05/09/23 Cogent Biosciences expects cash to fund operations into 2025 04/17/23 Cogent Biosciences presents nonclinical data at AACR 03/17/23 Cogent Biosciences treatment of mastocytosis granted orphan status 01/09/23 Cogent Biosciences announces planned milestones for 2023 COGT Cogent Biosciences $12.97 / +0.245 (+1.93%) 04/27/23 Baird Cogent Biosciences initiated with Outperform, $20 target at Baird 04/27/23 Baird Cogent Biosciences initiated with an Outperform at Baird 04/17/23 Wedbush Wedbush remains bullish on Cogent, says APEX Part 2 likely to succeed 03/27/23 H.C. Wainwright Cogent Biosciences assumed with a Buy at H.C. Wainwright COGT Cogent Biosciences $12.97 / +0.245 (+1.93%) 05/09/23 Cogent Biosciences reports Q1 EPS (54c), consensus (57c) 03/14/23 Cogent Biosciences reports Q4 EPS (56c), consensus (52c) 14 Jun COGT Cogent Biosciences $12.97 / +0.245 (+1.93%) 04/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/07/23 Cogent Biosciences Inc

Events

Earnings calls, analyst events, roadshows and more

Tomorrow at 00:00

2023 ASCO Annual Meeting Conferences

Chicago, IL
AXP ...
Tomorrow at 00:00

FinTech Virtual Bus Tour Conferences

Virtual Tour
Tomorrow at 00:00

Truist Hosted Company Events at 2023 ASCO Annual Meeting Conferences

Chicago, IL
AKR
Tomorrow at 00:00

Acadia Realty Trust Firm Sponsored Meetings

New York, NY
HOOD
Tomorrow at 00:00

Robinhood Firm Sponsored Meetings

Boston, MA
CCK
Tomorrow at 00:00

Crown Holdings Firm Sponsored Meetings

Virtual Meeting
FVRR
Tomorrow at 00:00

Fiverr Firm Sponsored Meetings

New York, NY
OVV
Tomorrow at 00:00

Ovintiv Firm Sponsored Meetings

Midwest
TGI
Tomorrow at 00:00

Triumph Group Firm Sponsored Meetings

New York, NY
CROX
Tomorrow at 00:00

Crocs Firm Sponsored Meetings

Toronto

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	SXTP X SXTP 60 Degrees Pharmaceuticals IPO Managers: WallachBeth $4.30-6.30 1.415M Shares
Fri	No deals

View All Syndicate Announcements »

Cincinnati Financial announces preliminary Q4 pretax catastrophe losses of $141M

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access